You are here: Industry Insights > Novartis

News List

Novartis division Sandoz recalls one lot of blood pressure drug expressbpd
November 12, 2018
The drug is made by China’s Zhejiang Huahai Pharmaceutical
As Novartis' other cancer launches struggle, Lutathera gets off to flying start fiercepharma
November 11, 2018
Novartis has stumbled with a couple of its recent cancer launches, namely the complicated CAR-T rollout for Kymriah and come-from-behind Kisqali debut. But not so with Lutathera.
Novartis R&D update highlights industry leading development pipeline including potential blockbusters and advanced therapy platforms worldpharmanews
November 06, 2018
Throughout 2018, Novartis took strong action to focus the company and its capital towards the Innovative Medicines Division...
Novartis to cut drug research projects by 20% pharmaceutical-technology
November 02, 2018
Novartis is reportedly planning to cease approximately 20% of its drug research projects, following a strategic review, in order to focus on other priority therapeutic areas.
Pfizer and Novartis partner up to develop combo therapies for NASH pharmafile
October 31, 2018
Pfizer and Novartis are set to team up in a non-exclusive partnership aimed at the clinical development of one or more combo therapies for the treatment of non-alcoholic steatohepatitis (NASH).
Novartis, Pfizer Partner for NASH contractpharma
October 30, 2018
Novartis, Pfizer Partner for NASH
Novartis Receives Approval for Cosentyx Label Update in Europe americanpharmaceuticalreview
October 30, 2018
Novartis Receives Approval for Cosentyx Label Update in Europe
Novartis Announces Clinical Collaboration with Pfizer americanpharmaceuticalreview
October 30, 2018
Novartis Announces Clinical Collaboration with Pfizer
Novartis, Pfizer join forces on potentially lucrative fatty liver disease expressbpd
October 30, 2018
The collaboration will help develop combination therapies involving medicines they have been working on separately to treat non-alcoholic steatohepatitis, or NASH
Novartis to acquire US cancer drug developer Endocyte for $2.1bn pharmaceutical-technology
October 22, 2018
The completion of the acquisition is conditional on customary closing conditions, including shareholder approval and regulatory approvals.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page